138 related articles for article (PubMed ID: 35243036)
41. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
Hoffmann L; Persson GF; Nygård L; Nielsen TB; Borrisova S; Gaard-Petersen F; Josipovic M; Khalil AA; Kjeldsen R; Knap MM; Kristiansen C; Møller DS; Ottosson W; Sand H; Thing R; Pøhl M; Schytte T
Radiother Oncol; 2022 Jun; 171():53-61. PubMed ID: 35421513
[TBL] [Abstract][Full Text] [Related]
42. Feasibility of spine stereotactic body radiotherapy for patients with large tumors in multiple vertebrae undergoing re-irradiation: Dosimetric challenge using 3 different beam delivery techniques.
Furuya T; Phua JH; Ito K; Karasawa K
Med Dosim; 2019 Winter; 44(4):415-420. PubMed ID: 30929978
[TBL] [Abstract][Full Text] [Related]
43. Treatment plan optimisation for reirradiation.
Murray L; Thompson C; Pagett C; Lilley J; Al-Qaisieh B; Svensson S; Eriksson K; Nix M; Aldred M; Aspin L; Gregory S; Appelt A
Radiother Oncol; 2023 May; 182():109545. PubMed ID: 36813170
[TBL] [Abstract][Full Text] [Related]
44. Comparison of VMAT-SABR treatment plans with flattening filter (FF) and flattening filter-free (FFF) beam for localized prostate cancer.
Chung JB; Kim JS; Eom KY; Kim IA; Kang SW; Lee JW; Kim JY; Suh TS
J Appl Clin Med Phys; 2015 Nov; 16(6):302–313. PubMed ID: 26699585
[TBL] [Abstract][Full Text] [Related]
45. Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study.
Bai Y; Gao XS; Qin SB; Chen JY; Su MM; Liu Q; Qin XB; Ma MW; Zhao B; Gu XB; Xie M; Cui M; Qi X; Li XY
Onco Targets Ther; 2018; 11():2571-2579. PubMed ID: 29780250
[TBL] [Abstract][Full Text] [Related]
46. Boost modalities in cervical cancer: dosimetric comparison between intracavitary BT vs. intracavitary + interstitial BT vs. SBRT.
Benkhaled S; Diakité K; Jullian N; Poeta S; Vandekerkhove C; Van Houtte P; Van Gestel D; De Caluwé A
Radiat Oncol; 2023 Jun; 18(1):105. PubMed ID: 37381016
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk.
Schneiders FL; van Vliet C; Giraud N; Bruynzeel AME; Slotman BJ; Palacios MA; Senan S
Clin Transl Radiat Oncol; 2023 Nov; 43():100680. PubMed ID: 37808454
[TBL] [Abstract][Full Text] [Related]
48. Assessing the Need for Adjusted Organ-at-Risk Planning Goals for Patients Undergoing Adjuvant Radiation Therapy for Locally Advanced Breast Cancer with Proton Radiation.
DeCesaris CM; Pollock A; Zhang B; Poirier Y; Kowalski E; Paulosky K; Mishra MV; Nichols E
Pract Radiat Oncol; 2021; 11(2):108-118. PubMed ID: 33109494
[TBL] [Abstract][Full Text] [Related]
49. Comparison of dose distributions and organs at risk (OAR) doses in conventional tangential technique (CTT) and IMRT plans with different numbers of beam in left-sided breast cancer.
Ayata HB; Güden M; Ceylan C; Kücük N; Engin K
Rep Pract Oncol Radiother; 2011; 16(3):95-102. PubMed ID: 24376964
[TBL] [Abstract][Full Text] [Related]
50. The dosimetric advantages of perirectal hydrogel spacer in men with localized prostate cancer undergoing stereotactic ablative radiotherapy (SABR).
Sturt P; Suh YE; Khoo V
Med Dosim; 2022 Summer; 47(2):173-176. PubMed ID: 35277316
[TBL] [Abstract][Full Text] [Related]
51. Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials.
Gerhard SG; Palma DA; Arifin AJ; Louie AV; Li GJ; Al-Shafa F; Cheung P; Rodrigues GB; Bassim CW; Corkum MT
Pract Radiat Oncol; 2021; 11(4):e355-e365. PubMed ID: 34217495
[TBL] [Abstract][Full Text] [Related]
52. Semiautomated head-and-neck IMRT planning using dose warping and scaling to robustly adapt plans in a knowledge database containing potentially suboptimal plans.
Schmidt M; Lo JY; Grzetic S; Lutzky C; Brizel DM; Das SK
Med Phys; 2015 Aug; 42(8):4428-34. PubMed ID: 26233173
[TBL] [Abstract][Full Text] [Related]
53. Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy.
Ojerholm E; Kirk ML; Thompson RF; Zhai H; Metz JM; Both S; Ben-Josef E; Plastaras JP
Acta Oncol; 2015; 54(8):1209-17. PubMed ID: 25734796
[TBL] [Abstract][Full Text] [Related]
54. Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation.
Choi JI; Khan AJ; Powell SN; McCormick B; Lozano AJ; Del Rosario G; Mamary J; Liu H; Fox P; Gillespie E; Braunstein LZ; Mah D; Cahlon O
Radiother Oncol; 2021 Dec; 165():142-151. PubMed ID: 34688807
[TBL] [Abstract][Full Text] [Related]
55. Dose delivery reproducibility for PBS proton treatment of breast cancer patients with and without mask immobilization.
Kang Y; Bues M; Halyard MY; McGee LA; Vern-Gross TZ; Wong WW; Keole SR; Vargas C; James SE; Ahmed SK; Archuleta JP; Ridgway AK; Lara PR; Fatyga M
Radiat Oncol; 2023 Sep; 18(1):157. PubMed ID: 37736727
[TBL] [Abstract][Full Text] [Related]
56. Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.
Leung E; Gladwish A; Sahgal A; Lo SS; Kunos CA; Lanciano RM; Mantz CA; Guckenberger M; Zagar TM; Mayr NA; Chang AR; Jorcano S; Biswas T; Pontoriero A; Albuquerque KV
Radiat Oncol; 2020 Jan; 15(1):24. PubMed ID: 32000833
[TBL] [Abstract][Full Text] [Related]
57. Stereotactic ablative radiation therapy with volumetric modulated arc therapy in flattening filter-free mode for low-, intermediate-, and high-risk prostate cancer patients: Are 2 arcs better than 1?
Fortin D; Mestrovic A; Alexander A
Pract Radiat Oncol; 2015; 5(5):e489-e497. PubMed ID: 26055612
[TBL] [Abstract][Full Text] [Related]
58. Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer.
Schiff JP; Price AT; Stowe HB; Laugeman E; Chin RI; Hatscher C; Pryser E; Cai B; Hugo GD; Kim H; Badiyan SN; Robinson CG; Henke LE
Radiother Oncol; 2022 Oct; 175():144-151. PubMed ID: 36063981
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus TomoTherapy.
Xhaferllari I; El-Sherif O; Gaede S
J Appl Clin Med Phys; 2016 Sep; 17(5):329-340. PubMed ID: 27685129
[TBL] [Abstract][Full Text] [Related]
60. Dosimetric comparison of brachyablation and stereotactic ablative body radiotherapy in the treatment of liver metastasis.
Pennington JD; Park SJ; Abgaryan N; Banerjee R; Lee PP; Loh C; Lee E; Demanes DJ; Kamrava M
Brachytherapy; 2015; 14(4):537-42. PubMed ID: 25944395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
